-
Hot Alert: BLUEPRINT MEDICINES CORP (NASDAQ:BPMC), Windstream Holdings (NASDAQ:WIN), Insulet Corporation (NASDAQ:PODD), Heartland Financial USA (NASDAQ:HTLF), Elephant Talk Communications (NYSEMKT:ETAK)
On Thursday shares of BLUEPRINT MEDICINES CORP (NASDAQ:BPMC) closed at $22.50. On May 5, Blueprint Medicines (NASDAQ:BPMC) announced the closing of its initial public offering of 9,367,708 shares of common stock at a public offering price of $18.00 per share, including shares of common stock issued upon the full exercise by the underwriters of their…
-
Investors Alert: TD Ameritrade Holding Corporation (NYSE:AMTD), DryShips (NASDAQ:DRYS), Insulet Corporation (NASDAQ:PODD), Xilinx Inc. (NASDAQ:XLNX), AmerisourceBergen Corporation (NYSE:ABC)
On Monday shares of TD Ameritrade Holding Corporation (NYSE:AMTD) closed at $37.22. Company’s sales growth for last 5 years was 5.20% and EPS growth for next 5 years is recorded as 18.25%. TD Ameritrade Holding Corp. (NYSE:AMTD) said Monday that Steve Boyle will succeed Bill Gerber as chief financial officer at the conclusion of the…
-
Stocks in Focus: Insulet Corporation (NASDAQ:PODD), Office Depot (NASDAQ:ODP), Noranda Aluminum Holding Corp. (NYSE:NOR), Roundy’s (NYSE:RNDY), Alibaba Group Holding (NYSE:BABA)
Shares of Insulet Corp. (NASDAQ:PODD) fell before recovering to $30.63 after JPMorgan downgraded the company to “neutral” from “overweight,” and cut its price target to $35 from $45 following reduced 2014 fourth quarter and full year guidance. On Thursday shares of Insulet Corporation (NASDAQ:PODD) closed at $31.86. Company’s sales growth for last 5 years was…
-
Small Cap Losers: Arena Pharmaceuticals (NASDAQ:ARNA), FuelCell Energy Inc. (NASDAQ:FCEL), Frontline (NYSE:FRO), ZIOPHARM Oncology (NASDAQ:ZIOP), Insulet Corporation (NASDAQ:PODD)
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has started with its Phase 2 clinical trial of ralinepag that is an oral IP receptor agonist for curing pulmonary arterial hypertension. It will be a 22-week, placebo controlled, double-blind and randomized trial. On Thursday shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) closed at $5.20. Company’s sales growth for last 5 years…
-
Top Losers at NYSE: Banco Santander, S.A. (NYSE:SAN), Kate Spade & Company (NYSE:KATE), Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI), InvenSense (NYSE:INVN), Insulet (NASDAQ:PODD)
Banco Santander, S.A. (NYSE:SAN) announced a cash dividend. Payment of $0.180165 per share is scheduled to be paid on February 09, 2015. Shareholders who purchased SAN stock prior to the ex-dividend date are eligible for the cash dividend payment. This represents an -4.65% decrease from the prior quarter. On Thursday shares of Banco Santander, S.A.…
-
Healthcare Stocks Top Losers: Insulet Corporation (NASDAQ:PODD), Infinity Pharmaceuticals (NASDAQ:INFI), Stemline Therapeutics (NASDAQ:STML), Brainstorm Cell Therapeutics (NASDAQ:BCLI), Atossa Genetics (NASDAQ:ATOS)
Insulet Corporation (NASDAQ:PODD) the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, plans to participate in the 33rd Annual J.P. Morgan Healthcare Conference taking place in San Francisco. Management is scheduled to present an overview of the Company on Wednesday, January 14, 2015 at 1:30 p.m. Pacific Time.On Thursday shares of…
-
Big Movers: Exelon Corporation (NYSE:EXC), Insulet Corporation (NASDAQ:PODD), Cardiome Pharma Corp. (NASDAQ:CRME), Boulder Brands (NASDAQ:BDBD), Auspex Pharmaceuticals (NASDAQ:ASPX)
Michael J. Pacilio, Exelon Nuclear’s president and chief nuclear officer since 2010, has been named executive vice president and chief operating officer of Exelon Generation LLC, the company announced, which is a business unit of Exelon Generation, which is a subsidiary of Exelon Corporation (NYSE:EXC). Bryan Hanson, Exelon Nuclear COO, has been promoted to senior…
-
Pre-market Decliners in Focus: Infinity Pharmaceuticals (NASDAQ:INFI), Insulet (NASDAQ:PODD), GW Pharmaceuticals plc (NASDAQ:GWPH), Alexion Pharmaceuticals (NASDAQ:ALXN), GoPro (NASDAQ:GPRO)
Infinity Pharmaceuticals Inc. (NASDAQ:INFI) announced that ASPIRA, a Phase 2 study of duvelisib, an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, with background methotrexate in patients with moderate-to-severe rheumatoid arthritis did not meet its primary endpoint. Infinity said it will continue to analyze the study results and expects to submit the data for publication in…
-
Notable Stocks in Focus: ArcelorMittal SA (ADR) (NYSE:MT), General Electric Company (NYSE:GE), Lions Gate Entertainment Corp. (NYSE:LGF), Diana Shipping (NYSE:DSX), Insulet (NASDAQ:PODD)
ArcelorMittal SA (ADR) (NYSE:MT) announced conference,13 February 2015: earnings release Q4 2014 and full year 2014. ArcelorMittal SA (ADR) (NYSE:MT) in last trading activity moved down -0.58% to close at $10.28. Company weekly performance is -7.97% while its quarterly performance stands at -20.49%. ArcelorMittal SA (ADR) (NYSE:MT) is -42.38% away from its 52 week high.…